First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer

By Meulenbeld Hielke J.   Creemers Geert-Jan  

Drugs & Aging, Vol. 24, Iss. 3, 2007-01 ,pp. : 223-238

Adis International

Access to resources Recommend Favorite

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer

By Gartner Elaina   Griffith Kent   Pan Quintin   Brewer George   Henja Gwen   Merajver Sofia   Zalupski Mark  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 159-165

Springer Publishing Company

Access to resources Recommend Favorite

Use of Bevacizumab in Metastatic Colorectal Cancer: Report from the Mexican Opinion and Analysis Forum on Colorectal Cancer Treatment with Bevacizumab (September 2009)

By Zinser-Sierra Juan W.  

Drugs in R&D, Vol. 11, Iss. 2, 2011-06 ,pp. : 101-111

Adis International

Access to resources Recommend Favorite

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab: A Review of its Use in Metastatic Colorectal Cancer

By McCormack Paul L.   Keam Susan J.  

Drugs, Vol. 68, Iss. 4, 2008-01 ,pp. : 487-506

Adis International

Access to resources Recommend Favorite